Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo

Zhou,Zijun; Jiang,Hua; Xia,Jiejun; Zhang,Jing

doi:10.3892/ijo.2020.5085

Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo

Authors:
- Zijun Zhou
- Hua Jiang
- Jiejun Xia
- Jing Zhang
View Affiliations

Affiliations: Department of Interventional Radiology and Vascular Anomalies, Guangzhou Women and Children's Medical Center of Guangzhou Medical University, Guangzhou, Guangdong 510627, P.R. China
Published online on: June 22, 2020 https://doi.org/10.3892/ijo.2020.5085
Pages: 697-706
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retinoblastoma (RB) is one of the most aggressive malignancies affecting infants and children. Platinum drugs are commonly used in the treatment of RB; however, their efficacy is often compromised by drug resistance and severe toxicity. The present study aimed to investigate and compare the toxicity and antitumor activity of the third‑generation platinum drugs, carboplatin and lobaplatin, in vitro and in vivo. The Y79 RB cell line was treated with carboplatin or lobaplatin in vitro and then used to establish xenografts in immunodeficient nude mice in vivo; the effects of pharmacological doses of these drugs were then assessed. High concentrations of carboplatin and lobaplatin markedly inhibited Y79 RB cell proliferation in vitro. In addition, the lobaplatin group exhibited higher proportions of early‑stage apoptotic cells than the carboplatin group, while no significant differences in the proportions of cells in the S phase were observed between the 2 groups, as shown by flow cytometry. Significant changes in the E2F1/Cdc25a/Cdk2 pathway in the RB cells were detected by RNA‑seq following carboplatin or lobaplatin intervention. RT‑qPCR, immunofluorescence and immunohistochemical analyses in vivo and in vitro demonstrated that the trends of drug‑induced inhibition of tumor pathological changes may have been regulated through the E2F1/Cdc25a/Cdk2 pathway, and that lobaplatin was more effective than carboplatin in controlling tumors in vivo. On the whole, the findings of the present study demonstrate that lobaplatin is associated with lower cytotoxicity and exerts more prominent therapeutic effects than carboplatin on Y79 RB cells in vitro and in mice in vivo.

View Figures

View References

1	Hayden B, Jockovich ME, Murray TG, Kralinger MT, Voigt M, Hernandez E, Feuer W and Parel JM: Iontophoretic delivery of carboplatin in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 47:3717–3721. 2006. View Article : Google Scholar : PubMed/NCBI
2	Castillo BV Jr and Kaufman L: Pediatric tumors of the eye and orbit. Pediatr Clin North Am. 50:149–172. 2003. View Article : Google Scholar : PubMed/NCBI
3	Wiman KG: The retinoblastoma gene: Role in cell cycle control and cell differentiation. FASEB J. 7:841–845. 1993. View Article : Google Scholar : PubMed/NCBI
4	MacCarthy A, Birch JM, Draper GJ, Hungerford JL, Kingston JE, Kroll ME, Onadim Z, Stiller CA, Vincent TJ and Murphy MF: Retinoblastoma in Great Britain 1963-2002. Br J Ophthalmol. 93:33–37. 2009. View Article : Google Scholar
5	Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT and Shields JA: The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 113:2276–2280. 2006. View Article : Google Scholar : PubMed/NCBI
6	Abramson DH, Lawrence SD, Beaverson KL, Lee TC, Rollins IS and Dunkel IJ: Systemic carboplatin for retinoblastoma: Change in tumour size over time. Br J Ophthalmol. 89:1616–1619. 2005. View Article : Google Scholar : PubMed/NCBI
7	Yanık Ö, Gündüz K, Yavuz K, Taçyıldız N and Ünal E: Chemotherapy in retinoblastoma: Current approaches. Turk J Ophthalmol. 45:259–267. 2015. View Article : Google Scholar
8	Smith SJ, Smith BD and Mohney BG: Ocular side effects following intravitreal injection therapy for retinoblastoma: A systematic review. Br J Ophthalmol. 98:292–297. 2014. View Article : Google Scholar
9	Winter U, Buitrago E, Mena HA, Del Sole MJ, Laurent V, Negrotto S, Francis J, Arana E, Sgroi M and Croxatto JO: et a l: Pharmacokinetics, safety, and efficacy of intravitreal digoxin in preclinical models for retinoblastoma. Invest Ophthalmol Vis Sci. 56:4382–4393. 2015. View Article : Google Scholar : PubMed/NCBI
10	McKeage MJ: Lobaplatin: A new antitumour platinum drug. Expert Opin Investig Drugs. 10:119–128. 2001. View Article : Google Scholar
11	Shan L, Bai B, Lv Y, Xie B, Huang X and Zhu H: Lobaplatin suppresses proliferation and peritoneal metastasis of colorectal cancer in a preclinical model. Biomed Pharmacother. 108:486–491. 2018. View Article : Google Scholar : PubMed/NCBI
12	Yin CY, Lin XL, Tian L, Ye M, Yang XY and Xiao XY: Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis. World J Gastroenterol. 20:17426–17433. 2014. View Article : Google Scholar : PubMed/NCBI
13	Xie CY, Xu YP, Jin W and Lou LG: Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Anticancer Drugs. 23:698–705. 2012. View Article : Google Scholar : PubMed/NCBI
14	Chen L, Cao H, Yu C and Feng Y: Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal. Fundam Clin Pharmacol. 32:548–557. 2018. View Article : Google Scholar : PubMed/NCBI
15	Wheate NJ, Walker S, Craig GE and Oun R: The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 39:8113–8127. 2010. View Article : Google Scholar : PubMed/NCBI
16	Zhang Q, Cheng Y, Huang L, Bai Y, Liang J and Li X: Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an in vitro and in vivo model. Oncol Lett. 14:5326–5332. 2017.PubMed/NCBI
17	Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, Dunkel IJ, Antoneli CB, Greenwald M, Haik BG, Leal CA, et al: Secondary acute myelogenous leukemia in patients with retinoblastoma: Is chemotherapy a factor? Ophthalmology. 114:1378–1383. 2007. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P and Sikic BI: Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol. 8:1231–1239. 2014. View Article : Google Scholar : PubMed/NCBI
20	Liang H, Liu HZ, Wang HB, Zhong JY, Yang CX and Zhang B: Dexmedetomidine protects against cisplatin induced acute kidney injury in mice through regulating apoptosis and inflammation. Inflamm Res. 66:399–411. 2017. View Article : Google Scholar : PubMed/NCBI
21	Tamboli A, Podgor MJ and Horm JW: The incidence of retinoblastoma in the United States 1974 through 1985. Arch Ophthalmol. 108:128–132. 1990. View Article : Google Scholar : PubMed/NCBI
22	Kim DY, Choi JA, Koh JY and Yoon YH: Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma. J Exp Clin Cancer Res. 35:1712016. View Article : Google Scholar : PubMed/NCBI
23	Balmer A, Zografos L and Munier F: Diagnosis and current management of retinoblastoma. Oncogene. 25:5341–5349. 2006. View Article : Google Scholar : PubMed/NCBI
24	Dilruba S and Kalayda GV: Platinum-based drugs: Past, present and future. Cancer Chemother Pharmacol. 77:1103–1124. 2016. View Article : Google Scholar : PubMed/NCBI
25	Buckingham R, Fitt J and Sitzia J: Patients' experiences of chemotherapy: Side-effects of carboplatin in the treatment of carcinoma of the ovary. Eur J Cancer Care (Engl). 6:59–71. 1997. View Article : Google Scholar
26	Kooijmans EC, Bökenkamp A, Tjahjadi NS, Tettero JM, van Dulmen-den Broeder E, van der Pal HJ and Veening MA: Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. 3:CD0089442019.PubMed/NCBI
27	Zhang H, Chen R, Wang X, Zhang H, Zhu X and Chen J: Lobaplatin-induced apoptosis requires p53-mediated p38MAPK activation through ROS generation in non-small-cell lung cancer. Front Oncol. 9:5382019. View Article : Google Scholar : PubMed/NCBI
28	Wu Y, Xu XY, Yan F, Sun WL, Zhang Y, Liu DL and Shen B: Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer. OncoTargets Ther. 12:4849–4857. 2019. View Article : Google Scholar
29	Du L, Fei Z, Song S and Wei N: Antitumor activity of lobaplatin against esophageal squamous cell carcinoma through caspase dependent apoptosis and increasing the Bax/Bcl 2 ratio. Biomed Pharmacother. 95:447–452. 2017. View Article : Google Scholar : PubMed/NCBI
30	Hua S, Kong X, Chen B, Zhuang W, Sun Q, Yang W, Liu W and Zhang Y: Anticancer mechanism of lobaplatin as monotherapy and in combination with paclitaxel in human gastric cancer. Curr Mol Pharmacol. 11:316–325. 2018. View Article : Google Scholar : PubMed/NCBI
31	Pan S, Sun Y, Sui D, Yang T, Fu S, Wang J, Hui B, Xi R, He C and Zhang X: Lobaplatin promotes radiosensitivity, induces apoptosis, attenuates cancer stemness and inhibits proliferation through PI3K/AKT pathway in esophageal squamous cell carcinoma. Biomed Pharmacother. 102:567–574. 2018. View Article : Google Scholar : PubMed/NCBI
32	Sun X, Lou LG, Sui DH and Wu XH: Preclinical activity of loba-platin as a single agent and in combination with taxanes for ovarian carcinoma cells. Asian Pac J Cancer Prev. 15:9939–9943. 2014. View Article : Google Scholar
33	Zhang CY, Bao W and Wang LH: Downregulation of p16(ink4a) inhibits cell proliferation and induces G1 cell cycle arrest in cervical cancer cells. Int J Mol Med. 33:1577–1585. 2014. View Article : Google Scholar : PubMed/NCBI
34	Korah J, Canaff L and Lebrun JJ: The retinoblastoma tumor suppressor protein (pRb)/E2 promoter binding factor 1 (E2F1) pathway as a novel mediator of TGFbeta induced autophagy. J Biol Chem. 291:2043–2054. 2016. View Article : Google Scholar
35	Sheldon LA: Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein. Cell Cycle. 16:2058–2072. 2017. View Article : Google Scholar : PubMed/NCBI
36	Yang Y and Peng XW: The silencing of long non-coding RNA ANRIL suppresses invasion, and promotes apoptosis of retino-blastoma cells through the ATM-E2F1 signaling pathway. Biosci Rep. 38:BSR201805582018. View Article : Google Scholar
37	Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev. 12:2245–2262. 1998. View Article : Google Scholar : PubMed/NCBI
38	Kent LN, Bae S, Tsai SY, Tang X, Srivastava A, Koivisto C, Martin CK, Ridolfi E, Miller GC, Zorko SM, et al: Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. J Clin Invest. 127:830–842. 2017. View Article : Google Scholar : PubMed/NCBI
39	Müller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD and Helin K: E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 15:267–285. 2001. View Article : Google Scholar : PubMed/NCBI
40	Poppy Roworth A, Ghari F and La Thangue NB: To live or let die - complexity within the E2F1 pathway. Mol Cell Oncol. 2:e9704802015. View Article : Google Scholar : PubMed/NCBI